We have a history of establishing value-creating collaborations with partners who bolster our capabilities.
Our strategic collaborations with leading global pharmaceutical companies allow us to advance our pipeline, validate our technology, and help streamline our efforts in bringing medicines patients in need.
|Bemarituzumab (FPA144) License and Collaboration Agreement||December 2017|
|Cabiralizumab (FPA008) License and Collaboration Agreement||October 2015|
|Fibrosis and CNS||March 2013|
|Respiratory Diseases||April 2012|